Protagonist Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PTGX$135.90+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| | 2023 | 2022 | ||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $186,727 | | $125,744 | ||
| Marketable securities | | | 154,890 | | | 111,611 |
| Receivable from collaboration partner | | | 10,000 | | | 10 |
| Prepaid expenses and other current assets | | | 3,960 | | | 5,712 |
| Total current assets | | | 355,577 | | | 243,077 |
| Property and equipment, net | | | 1,195 | | | 1,565 |
| Restricted cash - noncurrent | | | 225 | | | 225 |
| Operating lease right-of-use asset | | | 954 | | | 3,061 |
| Total assets | | $357,951 | | $247,928 | ||
| Liabilities and Stockholders’ Equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $772 | | $3,640 | ||
| Payable to collaboration partner | | | 3 | | | 69 |
| Accrued expenses and other payables | | | 19,358 | | | 24,955 |
| Operating lease liability - current | | | 1,141 | | | 2,515 |
| Total current liabilities | | | 21,274 | | | 31,179 |
| Operating lease liability - noncurrent | | | — | | | 1,141 |
| Total liabilities | | | 21,274 | | | 32,320 |
| Commitments and contingencies | | | | | | |
| Stockholders’ equity: | | | | | | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding | | | — | | | — |
| Common stock, $0.00001 par value, 90,000,000 shares authorized; 57,708,613 and 49,339,252 shares issued and outstanding as of December 31, 2023 and 2022, respectively | | | 1 | | | — |
| Additional paid-in capital | | | 952,491 | | | 752,722 |
| Accumulated other comprehensive loss | | | (105) | | | (359) |
| Accumulated deficit | | | (615,710) | | | (536,755) |
| Total stockholders’ equity | | | 336,677 | | | 215,608 |
| Total liabilities and stockholders’ equity | | $357,951 | | $247,928 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.